# Pilot Clinical Trial of the Safety and Efficacy of Telmisartan for the Mitigation of Pulmonary and Cardiac Complications in COVID-19 Patients

> **NCT04360551** · PHASE2 · TERMINATED · sponsor: **University of Hawaii** · enrollment: 24 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Telmisartan 40mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04360551
- **Lead sponsor:** University of Hawaii
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-07-01
- **Primary completion:** 2022-04-26
- **Final completion:** 2022-04-26
- **Target enrollment:** 24 (ACTUAL)
- **Why stopped:** Decrease in COVID-19 cases locally
- **Last updated:** 2023-08-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04360551

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04360551, "Pilot Clinical Trial of the Safety and Efficacy of Telmisartan for the Mitigation of Pulmonary and Cardiac Complications in COVID-19 Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04360551. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*